Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empegfilgrastim - Biocad

Next Previous
X
Search
Drug Profile

Empegfilgrastim - Biocad

Alternative Names: BCD-017; Extimia; Metpegfilgrastim

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 01 Jun 2016 Launched for Neutropenia (Prevention, Chemotherapy-induced) in Russia, Ukraine and India (SC) before June 2016
  • 01 Oct 2014 Biocad completes a phase III trial for Neutropenia (Prevention) in Russia, Ukraine & India (NCT02104830)
  • 03 Apr 2014 Biocad completes enrolment in its phase III trial for Neutropenia prevention in Russia, Ukraine & India (NCT02104830)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top